COO · Q2 2026 Earnings
BearishCooper Companies (The)
Reported June 4, 2026
Headline numbers
Key financials
Q2 FY2026| Metric | Q2 FY2026 | Q2 FY2025 | YoY | Q1 FY2026 | QoQ |
|---|---|---|---|---|---|
| Revenue | $1.08B | $1.00B | +7.9% | $1.02B | +5.6% |
| EPS | $1.21 | $0.96 | +26.0% | $1.10 | +10.0% |
| Gross margin | 68.0% | 68.0% | +0bps | 68.0% | +0bps |
| Operating margin | -3.0% | 18.0% | -2100bps | 21.0% | -2400bps |
| Free cash flow | $0.10B | $0.02B | +432.6% | $0.16B | -39.3% |
Guidance
Company narrowed full-year revenue and organic growth guidance downward by 100 bps, while maintaining EPS guidance and withdrawing specific FY2026 FCF forecast in favor of long-term objective.
Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.
Changes to prior guidance
| Metric | Period | Prior guide | New guide | Δ | Result |
|---|---|---|---|---|---|
| Revenue | FY 2026 | $4.306 - $4.346 billion | $4.285 - $4.321 billion | -$0.021 to -$0.025 billion (midpoint -$0.023B) | Lowered |
| Organic Revenue Growth | FY 2026 | 4.5% to 5.5% | 3.5% to 4.5% | -1.0 percentage points at both low and high end | Lowered |
| CooperVision Revenue | FY 2026 | $2.906 - $2.932 billion | $2.883 - $2.908 billion | -$0.023 to -$0.024 billion | Lowered |
| CooperVision Organic Growth | FY 2026 | 4.5% to 5.5% | 3.5% to 4.5% | -1.0 percentage points at both low and high end | Lowered |
| Free Cash Flow | FY 2026 | $600 - $625 million | Withdrawn — no replacement | — | Withdrawn |
Reaffirmed unchanged this quarter: CooperSurgical Revenue ($1.402 - $1.414 billion), CooperSurgical Organic Growth (4% to 5%), Non-GAAP Diluted EPS ($4.58 - $4.66), Free Cash Flow Objective (exceeding $2.2 billion (2026-2028))
Segment KPIs
Q2 FY2026| Segment | Q2 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|
| CooperVision | $0.724B | $0.67B | +8.0% |
| CooperSurgical | $0.358B | $0.333B | +7.6% |
| Toric and Multifocal | $0.365B | — | +7.0% |
| Sphere, Other | $0.359B | — | +1.0% |
| Office and Surgical | $0.214B | — | +4.0% |
| Fertility | $0.144B | — | +10.0% |
| CooperVision Organic Growth | 4% | 7% | — |
| CooperSurgical Organic Growth | 6% | 7% | — |
| Fertility Revenue Growth | 10% organic | — | — |
Other KPIs
Q2 FY2026| Segment | Q2 FY2026 | Q2 FY2025 | YoY |
|---|---|---|---|
| Americas | $0.303B | — | +7.0% |
| EMEA | $0.29B | — | +6.0% |
| Asia Pacific | $0.131B | — | -6.0% |
| Non-GAAP Operating Margin | 27% | 25% | — |
| Free Cash Flow | $96.4 million | — | — |
| Organic Revenue Growth | 5% | 7% | — |
Management tone
Answers to last quarter's watch list
What to watch into next quarter
Sources
- Cooper Companies Q2 FY2026 press release, filed 2026-06-04: https://www.sec.gov/Archives/edgar/data/711404/000162828026040823/cooperq22026pressrelease.htm
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.